Good Articles to Share
Pfizer says Covid booster shot 95.6pct effective
FRANKFURT: A booster shot of the anti-Covid-19 vaccine developed by Pfizer-BioNTech is 95.6 per cent effective against symptomatic infection, according to trial data published by the makers on Thursday.
The clinical phase three trial with "10,000 participants 16 years of age and older" showed "a relative vaccine efficacy of 95.6 per cent against disease during a period when Delta was the prevalent strain", the companies said in a statement.
The study presented the "first results" of a booster trial, with a third shot of the vaccine demonstrating a "favourable safety profile".
"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease," said Pfizer CEO Albert Bourla.
The preliminary results would be shared with regulatory agencies "as soon as possible", the companies said in the statement.
Several countries have already approved Covid-19 booster shots to increase immunity in people who have already been vaccinated, but whose protection may have dipped after several months, per some studies.
In the United States, the federal Food and Drug Administration (FDA) approved a third dose in September for everyone aged 65 and up, as well as people at high risk of developing severe Covid.
The European Medicines Agency (EMA) approved a booster for over-18s at the beginning of October, allowing national regulators to decide which groups should be eligible first.
In Israel, authorities have gone further, approving booster shots for everyone aged 12 and over.
– AFP
More articles on Good Articles to Share
Oil heads for weekly gains on anxiety over intensifying Ukraine war
Created by Tan KW | Nov 22, 2024
S&P lowers outlook on three Adani units after US indictment of founder
Created by Tan KW | Nov 22, 2024
Royal Mail owner IDS warns of cost pressures after return to profit
Created by Tan KW | Nov 22, 2024
Kenya's Ruto Scraps $2.6 Billion Adani Deals in Wake of US Indictment
Created by Tan KW | Nov 22, 2024
Adani Stocks Extend Slump After $27B Rout | Full Episode | Insight with Haslinda Amin 11/22/2024
Created by Tan KW | Nov 22, 2024
Discussions
Be the first to like this. Showing 2 of 2 comments
Pfizer was given the thumbs up earlier & was also rated the better vaccine among the few choices. Record however has proven that it's just another failed product, yet some Western media keeps promoting its effectiveness.
2021-10-22 07:42
Post a Comment
Featured Posts
Latest Videos
Apps
Top Articles
1
2
Good Articles to Share
A 30-Year Expert Trader’s HONEST Confession - Ziet Invests
3
4
Koon Yew Yin's Blog
6
BFM Podcast
7
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
MQ Trading Signals
Stock
Time
Signal
Duration
Stock
Time
Signal
Duration
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Tobby
Some dumbass already spinning about booster shots! Look, the initial vaccine are not perfect! Until they figure the right ingredient, we have to take this improve version of vaccine! It's just pure science!
2021-10-22 00:10